David P. Carbone, MD, PhD

An expert discusses how first-line nivolumab plus ipilimumab with limited chemotherapy provides durable survival benefits in metastatic NSCLC across PD-L1 levels and histologies, consistent with CheckMate 9LA.

David P. Carbone, MD, PhD, discusses the impact of immunotherapy on lung cancer.

David P. Carbone, MD, PhD, discusses the impact of immunotherapy on lung cancer.

David P. Carbone, MD, PhD, discusses the importance of personalizing immunotherapy for patients with non–small cell lung cancer.

David P. Carbone, MD, PhD, discusses a study evaluating acquired resistance to osimertinib in non–small cell lung cancer.

David P. Carbone, MD, PhD, director of the Thoracic Oncology Center at The Ohio State University Comprehensive Cancer Center–James, provides perspective on the novel coronavirus 2019 (COVID-19).

David P. Carbone, MD, PhD, a professor in the Division of Medical Oncology at the Ohio State University Comprehensive Cancer Center, discusses potential biomarkers in lung cancer.

David P. Carbone, MD, PhD, from the Ohio State University Comprehensive Cancer Center, discusses the exploration of immunotherapies as treatments for patients with advanced lung cancer.

David P. Carbone, MD, PhD, from the Ohio State University Comprehensive Cancer Center, describes variations in the accuracy and availability of genetic testing technologies.